Vanguard Group Inc. Has $143.49 Million Stock Holdings in LivaNova PLC $LIVN

Vanguard Group Inc. raised its stake in LivaNova PLC (NASDAQ:LIVN) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,332,051 shares of the company’s stock after purchasing an additional 34,812 shares during the quarter. Vanguard Group Inc.’s holdings in LivaNova were worth $143,491,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. State of Wyoming acquired a new stake in shares of LivaNova in the 2nd quarter valued at approximately $31,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares in the last quarter. Quarry LP bought a new stake in LivaNova during the third quarter worth $36,000. UMB Bank n.a. boosted its stake in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after purchasing an additional 306 shares in the last quarter. Finally, Bayforest Capital Ltd grew its holdings in shares of LivaNova by 44.8% during the third quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after purchasing an additional 284 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 2.5%

Shares of NASDAQ:LIVN opened at $70.09 on Tuesday. The stock’s 50-day moving average price is $64.02 and its 200-day moving average price is $62.38. LivaNova PLC has a 12-month low of $41.01 and a 12-month high of $72.78. The stock has a market capitalization of $3.85 billion, a P/E ratio of 35.94 and a beta of 0.82. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the previous year, the business earned $0.88 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts anticipate that LivaNova PLC will post 3.68 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on LIVN. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday. Barclays upped their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday. Mizuho upped their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a report on Wednesday, February 25th. Finally, Needham & Company LLC boosted their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $77.22.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.